Candida albicans vaccine - LigoCyte

Drug Profile

Candida albicans vaccine - LigoCyte

Alternative Names: CAV-6.1

Latest Information Update: 05 Feb 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator LigoCyte Pharmaceuticals
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Candidiasis

Most Recent Events

  • 14 Jul 2004 This programme is still in active development - BIO 2004 Annual International Convention (BIO-2004)
  • 30 Jul 2002 This programme is still in active development
  • 15 Oct 1999 Preclinical development for Candidiasis in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top